Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device Japan Approvals

AdvaMed Wary Of Japan's Ability To Improve Incremental Product Review

This article was originally published in PharmAsia News

Executive Summary

Japan is in need of device industry investment, but without the incentive of data exclusivity, the government needs to counter existing disincentives, says AdvaMed CEO.

You may also be interested in...



Chuikyo's Pilot For Premium Reimbursement Pricing Under Review: One Of Three Fates By Year-end

Japan To Announce Medical Device Reimbursement Cuts In Coming Weeks

Companies selling medical devices in Japan will be notified in the next few weeks of payment rate reductions for their products following the recent release of reimbursement rules for the 2010-2012 cycle

Japan Rolls Out Three-Tiered Review System For Medical Devices

Japan is rolling out a new three-track medical device review system based on the novelty of the product, Japanese device reviewers said

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Medical Device Japan Approvals
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC077038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By